We serve Chemical Name:4-pentylphenyl 4-pentylcyclohexanecarboxylate CAS:67589-72-4 to global customers since 2007, Pls send inquiry to info@nbinno.com or visit www.nbinno.com our official website should you have any interests. This site is for information only.
Chemical Name:4-pentylphenyl 4-pentylcyclohexanecarboxylate
CAS.NO:67589-72-4
Synonyms:4-n-pentylcyclohexanecarboxylic acid,4-pentylphenyl ester;5H5;4-Pentylphenyl trans-4-pentylcyclohexylcarboxylate;trans-4-Pentylcyclohexanecarboxylic acid 4-pentylphenyl ester;4-n-Pentylphenyl-4′-trans-n-pentylcyclohexylcarboxylate;4-PENTYLPHENYL-4”-TRANS-PENTYLCYCLOHEXYLCARBOXYLATE
Molecular Formula:C23H36O2
Molecular Weight:344.53100
HS Code:
Physical and Chemical Properties:
Melting point:N/A
Boiling point:444ºC at 760mmHg
Density:0.959g/cm3
Index of Refraction:1.497
PSA:26.30000
Exact Mass:344.27200
LogP:6.71140
Material Safety Information (Applicable for Hazard Chemicals)
RIDADR:
Packing Group:
Contact us for information like 4-n-pentylcyclohexanecarboxylic acid,4-pentylphenyl ester chemical properties,Structure,melting point,boiling point,density,molecular formula,molecular weight,4-PENTYLPHENYL-4”-TRANS-PENTYLCYCLOHEXYLCARBOXYLATE physical properties,toxicity information,customs codes,safety, risk, hazard and MSDS, CAS,cas number,trans-4-Pentylcyclohexanecarboxylic acid 4-pentylphenyl ester Use and application,4-Pentylphenyl trans-4-pentylcyclohexylcarboxylate technical grade,usp/ep/jp grade.
Related News: Novadiscovery (NOVA), a leading health tech company using in silico clinical trials to predict drug efficacy and optimize clinical trial development, today announces the appointment of Grégoire Boutonnet as Chief Operating Officer, effective immediately. Cypress Oil manufacturers A new post-hoc analysis of pooled data from the TULIP phase III clinical trials being presented at the annual European Congress of Rheumatology (EULAR 2021) showed anifrolumab was consistently associated with improvements in both skin rash and arthritis across three different disease measures each, compared to placebo, in patients with moderate to severe systemic lupus erythematosus (SLE). 3-cyano-4-phenylmethoxybenzoic acid suppliers Despite the $13 million first-quarter hit from the rate cut, iRhythm grew revenue year over year by 17% to $74.3 million in the quarter. iRhythm’s net losses for the quarter totaled $27.8 million, compared to a net loss of $9.1 million in the first quarter of 2020. Dimethyl 3,4-thiophenedicarboxylate vendor & factory.
